Arca Biopharma | ABIO - Operating Profit


Arca Biopharma reported $-36.43M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Amgen USD 4.61B 777M Jun/2026
Arca Biopharma USD -36.43M 2M Mar/2026
Biogen USD -243.8M 758.1M Jun/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cipla INR 8.88B 2.74B Jun/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
CSL USD 2.64B 1.97B Dec/2025
Cytokinetics USD -179.17M 2.05M Jun/2026
Daiichi Sankyo JPY 85.1B 4.44B Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Grifols EUR 320.55M 91.01M Dec/2025
Laboratory Of America USD 456.7M 46.6M Jun/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Otsuka Holdings JPY 140.41B 22.2B Jun/2026
Pfizer USD 667M 4.32B Jun/2026
United Therapeutics USD 330.8M 5M Jun/2026